[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura].
The efficacy and mechanism of interferon alpha-2a (IFN alpha-2a) were assessed in the treatment of chronic idiopathic thrombocytopenic purpura (cITP). 20 patients with cITP (treatment group) were treated with IFN alpha-2a 3MIU i.m. once a week for 8 weeks; 28 patients with cITP (control group) were treated with prednisone 1 mg/(kg.d) for 4 weeks. Blood platelet counts (BPC), megakaryocyte number, immunnological parameters, percent and absolute counts of reticulated platelets (RPs) and megakaryocyte colony formation units were observed before and after therapy. The results showed that the efficacy of IFN alpha-2a was better than that of corticosteroid, P < 0.05. The RPs% decreased and the platelet-producing megakaryocyte percentage increased from 11.43% to 33.19% significantly after IFN alpha-2a therapy, but there were no significant changes in immunnological parameters. These indicate that IFN alpha-2a is effective in treating cITP, the mechanism may be based on promoting the megakaryocyte development and activating the production of platelets.
Deng
C
C
Department of Haematology, First Affiliated Hospital, WCUMS, Chengdu 610041.
Niu
T
T
Xiang
X
X
Meng
W
W
Li
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D017252:CD3 Complex / Q000097:blood; D015704:CD4 Antigens / Q000097:blood*; D016827:CD8 Antigens / Q000097:blood; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins
D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins